Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment
- 1 February 2001
- journal article
- Published by Elsevier in The Breast
- Vol. 10 (1) , 67-77
- https://doi.org/10.1054/brst.2000.0225
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutationsNature Genetics, 1994
- A death in the life of p53Nature, 1993
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences, 1991
- The p53 tumour suppressor geneNature, 1991
- Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other NeoplasmsScience, 1990
- HER-2/neu oncogene protein and prognosis in breast cancer.Journal of Clinical Oncology, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985